Hoofddorp, the Netherlands, 09 August 2022. IGEA Pharma N.V. (SIX: IGPH) today announced the grant of a temporary exemption from its disclosure obligations with respect to the 2021 annual report.
Press releases/News
IGEA to get SIX further approval to the 2021 annual report disclosure
Hoofddorp, the Netherlands, 15 July 2022. IGEA Pharma N.V. (SIX: IGPH) today announced the grant of a temporary exemption from its disclosure obligations with respect to the 2021 annual report.
IGEA Pharma has announced that LMH – an industrial holding company – has completed the due diligence process for a euro 6.000.000 committment to fund the swiss CBD extraction facility
Hoofddorp, the Netherlands, 13th July 2022. Today IGEA Pharma N.V. (SIX: IGPH) has announced that LMH Holding has completed the due diligence process on the Company in relation to its Euro 6.0 million commitment to fund the GMP-Pharma CBD extraction facility owned through its joint-venture Blue Sky Swisse S.A.
IGEA to get SIX further approval to the 2021 annual report disclosure
Hoofddorp, the Netherlands, 15 June 2022. IGEA Pharma N.V. (SIX: IGPH) today announced the grant of a temporary exemption from its disclosure obligations with respect to the 2021 annual report.
IGEA Pharma has signed a preliminary agreement with LMH-an industrial holding company-for a euro 6.000.000 committment to fund the completion of its swiss CBD extraction facility.
Hoofddorp, the Netherlands, 8th June 2022. Today IGEA Pharma N.V. (SIX: IGPH) has signed a preliminary agreement with LMH Spa for a Euro 6.000.000 commitment to fund the completion of its GMP-Pharma CBD extraction facility owned through its joint-venture Blue Sky Swisse S.A.
IGEA to get SIX approval to delay the 2021 annual report disclosure
Hoofddorp, the Netherlands, 2 May 2022. IGEA Pharma N.V. (SIX: IGPH) today announced the grant of a temporary exemption from its disclosure obligations with respect to the 2021 annual report.
IGEA pharma non-executive board members resigned after completion of the first post-combination phase. New members to be nominated
Hoofddorp, the Netherlands, 1February 2022. Today the Board of Directors of IGEA Pharma N.V. (SIX: IGPH) has acknowledged the resignation of Mrs Giovanna Puppo, Mr Raffaele Bertoni, Mr Lieven Baten and Mr Massimiliano Colella as members of the Board of Directors. The resignation is effective as of 31 January 2022 and is motivated by personal reasons.
GBC AG Publishes initial equity research report with buy recommendation and price target of EUR 1.05
Hoofddorp, the Netherlands, 25 November 2021. IGEA Pharma N.V. (SIX: IGPH) receives an analyst vote. On Monday 22nd the research house GBC AG (www.gbc-ag.de/) publishes its first coverage equity research on the Company and from now on, GBC analysts Matthias Greiffenbergerand Felix Haugg will cover the further development of Igea Pharma NV with continuous assessment.
GBC AG to start equity coverage of IGEA Pharma
Hoofddorp, the Netherlands, 04October 2021. IGEA Pharma N.V. (SIX: IGPH) today announced that GBCAG (www.gbc-ag.de/) will begin a full-coverage equity research on the Company.
IGEA discloses its half-2021 financials
Hoofddorp, the Netherlands, 30September 2021. IGEA Pharma N.V. (SIX: IGPH) todayannounced the disclosure of its half-2021 financials.